CUVPOSA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for CUVPOSA (CUVPOSA).
Cuvposa (glycopyrrolate) is a competitive antagonist of muscarinic acetylcholine receptors (M1, M2, M3). It reduces salivary secretions by blocking parasympathetic nerve impulses in salivary glands, thereby decreasing the volume and frequency of drooling.
| Metabolism | Glycopyrrolate is minimally metabolized, primarily by the liver via ester hydrolysis and conjugation. It is not significantly metabolized by CYP450 enzymes. |
| Excretion | CUVPOSA (glycopyrrolate) is primarily eliminated unchanged in the urine (approximately 85% renal excretion of the absorbed dose) and feces (approximately 5% via biliary/fecal route). |
| Half-life | The terminal elimination half-life is approximately 0.6 to 1.2 hours after intravenous administration; in pediatric patients with neurologic conditions, the half-life may be prolonged up to 1.5 to 2.5 hours. This short half-life necessitates frequent dosing for sustained anticholinergic effects. |
| Protein binding | Glycopyrrolate is moderately protein bound (approximately 45% to 50%), primarily to albumin. |
| Volume of Distribution | The volume of distribution is approximately 0.4 to 0.6 L/kg, suggesting limited extravascular distribution and mainly remaining in the central compartment. |
| Bioavailability | Oral bioavailability is low and variable, approximately 1% to 5% due to poor absorption and extensive first-pass metabolism. |
| Onset of Action | After oral administration, the onset of action for reduction of drooling is typically within 1 to 2 hours. |
| Duration of Action | The duration of action for reduction of drooling is approximately 5 to 6 hours after a single oral dose, supporting three-times-daily dosing. Note: Individual response may vary. |
1 mg/mL oral solution: initial dose 0.02 mg/kg orally 3 times daily; titrate upward by 0.004 mg/kg per dose every 5–7 days to optimal effect; maximum single dose 0.1 mg/kg (not to exceed 1.5 mg per dose) or 0.2 mg/kg per dose (not to exceed 3 mg per dose) if benefit-risk justifies higher dose.
| Dosage form | SOLUTION |
| Renal impairment | No specific guidelines; use with caution in renal impairment. For severe renal impairment (eGFR <30 mL/min), consider dose reduction by 25-50% due to potential increased systemic exposure. |
| Liver impairment | No specific guidelines; use with caution in hepatic impairment. For moderate to severe hepatic impairment (Child-Pugh class B or C), consider dose reduction by 50% due to decreased metabolism. |
| Pediatric use | Administer as for adults: initial 0.02 mg/kg orally 3 times daily; titrate by 0.004 mg/kg per dose every 5–7 days; maximum single dose 0.1 mg/kg (not to exceed 1.5 mg) or up to 0.2 mg/kg (not to exceed 3 mg) if tolerated. |
| Geriatric use | Start at low end of dosing range (0.02 mg/kg) and titrate cautiously; monitor for anticholinergic adverse effects (e.g., constipation, confusion, urinary retention). Consider lower maintenance doses due to age-related decline in clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for CUVPOSA (CUVPOSA).
| Breastfeeding | It is not known whether glycopyrrolate is excreted in human milk. Caution should be exercised when administered to a nursing woman. The M/P ratio is unknown. Due to low oral bioavailability, risk to nursing infant may be low, but monitor for anticholinergic effects (e.g., constipation, dry mouth). |
| Teratogenic Risk | Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. In animal studies, glycopyrrolate (the active ingredient in CUVPOSA) was teratogenic in rabbits at doses approximately 0.7 times the maximum human dose. Fetal risks are unknown in humans; use only if potential benefit justifies potential risk to the fetus. First trimester: risk cannot be ruled out. Second and third trimesters: limited data, but theoretical risk of anticholinergic effects (e.g., fetal tachycardia, meconium ileus). |
■ FDA Black Box Warning
No FDA black box warning.
| Serious Effects |
["Absolute: Hypersensitivity to glycopyrrolate or any component of the formulation.","Relative: Glaucoma (angle-closure), obstructive uropathy, gastrointestinal obstruction, paralytic ileus, myasthenia gravis, severe ulcerative colitis, toxic megacolon, and unstable cardiovascular status."]
| Precautions | ["Anticholinergic effects: May cause constipation, urinary retention, blurred vision, heat intolerance, and reduced sweating leading to hyperthermia.","Use in patients with gastrointestinal obstruction, myasthenia gravis, or ulcerative colitis may worsen condition.","Monitor for signs of anticholinergic toxicity (e.g., delirium, tachycardia).","Not recommended for use in patients with glaucoma or severe renal impairment."] |
Loading safety data…
| Fetal Monitoring | Monitor fetal heart rate during labor and delivery due to potential anticholinergic effects (tachycardia). In pregnancy, monitor for maternal anticholinergic adverse effects (constipation, urinary retention, blurred vision). No specific fetal monitoring required outside standard obstetric care. |
| Fertility Effects | No human data on fertility effects. In animal studies, reduced sperm motility and fertility were observed at high doses. May potentially impair male and female fertility based on anticholinergic effects on reproductive function. |